序号	中文	英文	操作
151	Mark G Lewis, Bioqual Inc, USA	Mark G Lewis, Bioqual Inc, USA	查看中文全文00003 查看英文全文00003
152	Joshua Liang, Clover Biopharmaceuticals, China	Joshua Liang, Clover Biopharmaceuticals, China	查看中文全文00003 查看英文全文00003
153	Jinzhong Lin, on behalf of Fudan University, China	Jinzhong Lin, on behalf of Fudan University, China	查看中文全文00003 查看英文全文00003
154	Ira Longini, University of Florida, USA	Ira Longini, University of Florida, USA	查看中文全文00003 查看英文全文00003
155	Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa	Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa	查看中文全文00003 查看英文全文00003
156	Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA	Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA	查看中文全文00003 查看英文全文00003
157	Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research	Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research	查看中文全文00003 查看英文全文00003
158	Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA	Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA	查看中文全文00003 查看英文全文00003
159	Federico Martinón-Torres, Hospital Clínico Universitario de Santiago de Compostela, Spain	Federico Martinón-Torres, Hospital Clínico Universitario de Santiago de Compostela, Spain	查看中文全文00003 查看英文全文00003
160	Sebastian Maurer-Stroh, on behalf of the GISAID Initiative	Sebastian Maurer-Stroh, on behalf of the GISAID Initiative	查看中文全文00003 查看英文全文00003